INCY News and Press, Incyte Corporation From 11/02/23

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilimab, an anti-CSFR-1R monoclon...

2023-10-31 12:23:07 ET Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript October 31, 2023 08:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice Pre...

2023-10-31 07:01:29 ET More on Incyte Incyte: One Of The Most Undervalued Pharmaceuticals Incyte Q2: Revenue Growth Offset By Rising Operational Costs Incyte Q3 2023 Earnings Preview Incyte says study evaluating efficacy of ruxolitinib cream in children met p...

Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...

– Total revenues of $919 million in the third quarter (Q3'23) (+12% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $636 million (+3% Y/Y) in Q3'23, $1.9 billion (+8% Y/Y) YTD 2023, driven by growth in total patients across all indications; tightening full y...

Incyte Corporation (INCY) is expected to report $0.9 for Q3 2023

2023-10-30 12:33:41 ET More on Incyte Incyte: One Of The Most Undervalued Pharmaceuticals Incyte Q2: Revenue Growth Offset By Rising Operational Costs Incyte says study evaluating efficacy of ruxolitinib cream in children met primary endpoint FDA approves GSK...

Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized...

2023-10-18 12:49:03 ET Summary Incyte's stock has declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Despite the decline, Incyte reported strong financial performance with a 25% increase in net product revenu...

Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. "We look forward to sharing data from our oncology portfolio with the ...